Mustang Bio, Inc. (MBIO) announced that James Murphy, who served as the interim Chief Financial Officer, resigned on November 12, 2024. According to the company’s filing with the SEC on Friday, Murphy’s resignation was not due to any disagreement regarding the company’s operations, policies, or practices.On November 15, 2024, Mustang Bio’s Board of Directors appointed Manuel Litchman, the company’s President and Chief Executive Officer, to take on the role of Interim Chief Financial Officer, effective immediately.Earlier in the week, Mustang Bio reported that the Nasdaq Hearings Panel had approved the company’s request to extend deadlines to meet compliance requirements. The company has until January 31, 2025, to satisfy the $1 bid price requirement, and until February 18, 2025, to fulfill the $2.5 million stockholders’ equity requirement.The company stated it is exploring all available options to achieve compliance within the granted extension periods. However, it noted that there is no guarantee it will be successful in doing so.The material has been provided by InstaForex Company – www.instaforex.com
- UnitedHealth Confirms Killer Of CEO Brian Thompson And His Parents Was Not Company Member - December 14, 2024
- FDA Oks Checkpoint Therapeutics’ UNLOXCYT For Advanced Cutaneous Squamous Cell Carcinoma treatment - December 14, 2024
- Neurocrine’s CRENESSITY Gains FDA Approval For Treating Congenital Adrenal Hyperplasia - December 14, 2024
